From a therapeutic point of view, neutralization of CTGF with monoclonal antibody has been proved effective and now under stage I or II clinical trial for idiopathic pulmonary fibrosis, pancreatic cancer and DMD [39]. Here, CCN2 is linked to pulmonary fibrosis.